<DOC>
	<DOCNO>NCT01612078</DOCNO>
	<brief_summary>Orthostatic hypotension major complication hemodialysis interferes everyday activity hemodialysis patient . Since information regard use droxidopa clinical trial relate orthostatic hypotension chronic hemodialysis patient limited Taiwan , study design evaluation efficacy safety profile droxidopa orthostatic hypotension treatment / prevention hemodialysis patient .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Safety Droxidopa Orthostatic Hypotension Treatment Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>1 . Female male age great 20 year age 2 . Patient least 3 month document requirement regular hemodialysis session 3 . Patient decrease 20 mmHg SBP 10 mmHg DBP within 5 minute stand end hemodialysis least 2 3 session screen period . 4 . Subject subjective complain light headedness relate orthostatic hypotension AND VAS score 4 least 2 3 session screen period . 5 . Willing able comply study procedure sign write informed consent 1 . Female pregnant , lactate planning pregnant within 3 month , female childbearing potential use medically recognize method contraception 2 . Subject close angle glaucoma 3 . Subject severe hypertension 4 . Subject liver disorder 5 . Subject Hct great 36 % 6 . Subject confusion , hallucination , delusion 7 . Subject severe disease may limit survival study period , confound result study judged investigator , hyperthyroidism , artery stenosis , severe lung disorder , severe asthma , chronic open angle glaucoma , uncontrolled diabetic gangrene 8 . Subject take antihypotensive drug within 7 day prior randomization , midodrine , etilefrine amezinium 9 . Subject take ephedrine , pseudoephedrine within 7 day prior randomization 10 . Subject use investigational product within 4 week prior randomization 11 . Subject require blood transfusion within 3 month screen , suitable participate trial judge investigator 12 . Histories hypersensitive droxidopa 13 . Histories peripheral vascular disease , coronary artery disease suitable participate trial judge investigator 14 . Histories hemorrhage complication within 3 month screen visit , GI bleeding , intracranial bleeding traumatic hemorrhage , suitable participate trial judge investigator 15 . In investigator 's opinion , subject unlikely adequately cooperate follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>